Peer-Reviewed Evidence Highlights Vanoglipel’s Promise in Tackling Liver Fibrosis and MASH
New Publication Supports Anti-Fibrotic Mechanism for Vanoglipel in MASH
MetaVia Inc. (NASDAQ: MTVA), a clinical-stage biotechnology company focused on cardiometabolic diseases, announced today that a new, peer-reviewed study published in Biomolecules & Therapeutics supports the anti-fibrotic potential of vanoglipel (DA-1241), its lead GPR119 agonist candidate for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The study demonstrates that GPR119 agonists, like vanoglipel, can reduce liver fibrosis and suppress key signals that drive scar tissue formation in the liver—a critical factor for patients with metabolic liver disease.
Clinical Trial Results Align With Preclinical Findings
The published research independently validates mechanisms behind results seen in MetaVia’s recent Phase 2a clinical study, where vanoglipel treatment showed statistically significant improvements in several critical liver biomarkers. Specifically, trial data revealed a noteworthy decrease in the liver enzyme ALT and the fibrosis marker TIMP1, along with a 10.2% improvement from baseline in liver fibrosis (measured by VCTE), compared to a worsening (10.1% increase) for placebo after 16 weeks. Additionally, vanoglipel improved liver fat as measured by CAP score, and showed beneficial effects on HbA1c and tolerability.
| Measured Outcome | Vanoglipel Result | Placebo Result |
|---|---|---|
| VCTE Fibrosis Change (16 weeks) | -10.2% | +10.1% |
| ALT Levels | Statistically Significant Reduction | No Improvement |
| TIMP1 (Fibrosis Marker) | Statistically Significant Reduction | No Improvement |
| Liver Fat (CAP Score) | Improved | Worsened/Unchanged |
| HbA1c | Improvement | No Improvement |
Broader Therapeutic Potential in Liver Disease and Type 2 Diabetes
These findings and their alignment with clinical results reinforce vanoglipel’s case as a differentiated treatment option—not just for MASH but potentially for Type 2 Diabetes as well. By targeting GPR119 in the gut, vanoglipel promotes the release of metabolic-regulating peptides such as GLP-1, GIP, and PYY, which play pivotal roles in controlling blood sugar, lipid metabolism, and weight. MetaVia’s ongoing research indicates efficacy in preclinical models for both MASH and T2D, with consistent tolerability across human trials.
Investor Takeaway: Mechanistic Validation May Boost Confidence in Vanoglipel’s Path Forward
The independent validation from this peer-reviewed publication could boost confidence among investors and clinicians, especially as the company moves through critical clinical milestones. Having both mechanistic and real-world patient data lining up, vanoglipel’s dual metabolic and anti-fibrotic effects may set it apart in the crowded landscape of liver disease treatments.
MetaVia continues to pursue a broader development strategy for vanoglipel as either a standalone or combination therapy for patients with MASH and related metabolic diseases. This growing evidence base—spanning both the clinic and laboratory—suggests that vanoglipel may represent an important new tool in the fight against liver fibrosis.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI